Company news
Adicet Bio, Inc. news in 2025
Adicet Bio, Inc.'s news releases, calls and decks from 2025, newest first.
Adicet Bio Announces Reverse Stock Split
December 26, 2025
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
November 28, 2025
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 5, 2025
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 31, 2025
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
October 28, 2025
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
October 16, 2025
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis and Systemic Lupus Erythematosus
October 8, 2025
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
October 7, 2025
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
October 7, 2025
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 7, 2025
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
August 5, 2025
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
July 24, 2025
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference
May 21, 2025
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
May 6, 2025
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
April 30, 2025
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
April 28, 2025
Adicet Bio Appoints Michael Grissinger to the Board of Directors
April 17, 2025
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
March 31, 2025
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
March 6, 2025
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting
March 3, 2025
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)
February 27, 2025
Decks in 2025
- Corporate Update (October 2025)
Corporate update · 31 slides · Oct 7, 2025